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Abstract
The aim of the study: To study and evaluate platelets aggregation activity as primary phase of haemostasis and anti-platelet 
therapy in IHD patients after PCI, depending on the polymorphism of the gene ITGA 2 - C 807T.
Materials and methods: 54 patients who were on a treatment at the clinical hospital “Feofaniya” (Kyiv) and at the Kyiv 
Clinical Hospital on railway transport No. 2 were examined: 20 women and 34 men (mean age - 67.8±7.46 years). The study involved 
patients with stable forms of coronary artery disease (stable angina pectoris II-III) and acute coronary syndrome, with a history of 
percutaneous coronary intervention (PCI). All patients received antiplatelet therapy: acetylsalicylic acid (3.7 %), clopidogrel (9.3 %) 
or a combination of them (87 %).
Functional activity of the platelets was studied on a Biola Aggregation Analyzer laser agrometer. The response to antiplatelet 
therapy was confirmed by the Aggredyne test. The polymorphism of the C807T of the ITGA2 gene was determined by polymerase 
chain reaction (PCR).
Based on the results of the aggregation ability, antiplatelet therapy sensitivity, the patients were divided into two groups: 
group I - individuals with varying degrees of insensitivity to antiplatelet drugs (35 patients), group II – susceptible to treatment 
(19 patients). In each group was analyzed the polymorphism of the gene ITGA2 and features of the functional activity of the platelets, 
depending on the genotype.
Results: In 50 % of patients receiving ASA there was a different degree of non-sensitivity, with respect to thienopyridines – 
this figure was 20 %. Among patients who received dual antiplatelet therapy did not match at least one of the drugs - 83.3%. Among 
the “non responders” 78.9 % had a mutated T-allele, and a homozygous variant for the T allele was recorded in 53.15 % of patients, 





which has a clear link with the polymorphism of the gene ITGA 2. The presence of the T-allele in the genotype of patients with IHD 
is associated with a less adequate platelet response in patients receiving dual antiplatelet therapy for ASA and thienopyridines on 
ADP, which may have an effect on the sensitivity to thienopyridines.
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The myocardial revascularization has for almost half a century always remained as the main 
strategy in the treatment of coronary heart disease (CHD). In most cases, restoration of blood flow 
in the coronary arteries in patients with stable forms of coronary artery disease leads to objective 
improvement of the somatic status, and in patients with acute coronary syndrome, timely revascu-
larization of the myocardium saves lives. However, initiation of primary coronary intervention –
PCI (urgent or planned) does not mean eliminating the main problem that caused the need for these 
procedures –  systemic atherosclerosis. Progression of  cardiovascular disease  is  a  risk  factor  for 
recurrent ischemic incidents. To avoid them, the patient should receive optimal therapy aimed at 
reducing thrombocyte activity and preventing the formation of blood clots [1].
In recent years, with the increase in the frequency of percutaneous coronary interventions 
(PCI) with stenting, more and more attention is focused on solving the problems associated with 
thrombosis and restenosis within the stents. Restenosis inside the stent (in-stent restenosis-ISR) –
the process of healing a damaged vessel after stenting, is found in approximately 10–40 % of pa-
tients [2]. Thrombosis inside the stent is observed in about 0.87–2.2 % of cases and develops, as 
a rule, during the first year after stent placement [3, 4]. It is well known that vascular wall injury 
during an intervention results in the development of a local inflammatory reaction, adhesion, acti-
vation and aggregation of platelets with the formation of a posterior thrombus, migration and pro-
liferation of smooth muscle cells and re-endothelialization, as well as the synthesis of components 
of the extracellular matrix (hyaluronic acid, fibronectin, osteopontin, ivibronectin) [5].
The modern treatment of patients with acute myocardial infarction (AMI) with elevation 
of the ST segment includes a full list of antiplatelet drugs, including dual oral antiplatelet therapy 
(acetylsalicylic acid and thienopyridines) and anticoagulants. [6] Unfortunately, to date, there is 
not enough research that adequately evaluates the final results and the role of intravenous admin-
istration of IIb/IIIa glycoprotein receptor inhibitors in treating AMI patients with ST elevation [7].
Since atherothrombosis is the basis of vascular catastrophes, stabilization of haemostasis 
processes plays a key role in the treatment and prevention of coronary artery disease [8, 9]. But the 
constant use of antiplatelet agents is not able to completely protect the patient from acute cardiovas-
cular attacks. It turned out that despite the use of antiplatelet drugs, some people had no antiplatelet 
activity due to laboratory tests, the final cause of which has not yet been named.
According to various authors, aspirin resistance is a very common problem: the incidence of 
insensitivity to ASA in various studies varied from 6 to 47 %. Moreover, it has been proved that the 
emergence of acute cardiovascular situations in the treatment of ASA is a prognostic adverse factor 
and is accompanied by a higher risk of complications [10, 11]. Over time, this phenomenon has been 
confirmed with other antiplatelet drugs, especially the second most commonly used drug – clopidogrel.
But despite the enormous amount of clinical and experimental studies on this issue over 
the past decade, there is currently no consensus on mechanisms, resistance, and ways to overcome 
resistance to antiplatelet agents [12]. It is believed that resistance to antiplatelet may have multifac-
torial nature. One of the most important and frequent causes is the high activity of immune-inflam-
matory and prooxidant processes.
Over  the past 30 years, PCI has become widespread  in  the primary strategy  for  treating 
patients with stable coronary heart disease in all countries in Europe and America, even though the 
treatment recommendations give preference to in-patient intensive care, risk reduction and lifestyle 
interventions [13].
Recently, despite the use of antiplatelet therapy, more frequent restenosis of stents and re-
peated acute cardiovascular attacks became occured. Therefore, many modern studies addressed 
to the issue of studying this question and discuss the possible involvement of genetic factors in the 
development of these incidents [14, 15].
3. Aim of the study
To study and evaluate the aggregation activity of platelets as primary phase of haemostasis 
and antiplatelet therapy, in patients with IHD and PCI, depending on the polymorphism of the gene 
ITGA 2 – C 807T.
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4. Materials and methods
During the study were observed 54 patients that were on a treatment at the Department of 
acute coronary pathology, chronic ischemic heart disease of the clinical hospital “Feofaniya”, at 
the Department of intensive care and cardiology of the Kyiv Clinical Hospital on railway trans-
port No. 2: 20 women (37 %) and 34 men (63 %) at the age from 43 to 85 years (average age – 
67.8±7.46 years). The study involved patients with stable forms of coronary artery disease (stable 
angina pectoris II–III) and acute coronary syndrome, with a history of percutaneous coronary 
intervention (PCI). The treatment protocol was determined on the basis of European and Ukrainian 




should receive optimal drug therapy in accordance with the recommendations of the respective 
clinical protocol, as it has been proven to have a positive effect on the prognosis of the disease and 
the symptoms relief [16]. Dual antiplatelet therapy was prescribed to patients with stable forms 
of coronary heart disease after percutaneous coronary intervention [17]. The patient was given a 
primary PCI in a heart attack-dependent artery in the first hours of AMI with multi-vessel lesions 
with subsequent revascularization of the heart attack-independent arteries after 4 weeks of conser-
vative treatment [18]. All patients received antiplatelet therapy: acetylsalicylic acid (3.7 %), clopi-
dogrel (9.3 %) or a combination of them (87 %). During the examination of patients, an algorithmic 
standardized thematic outpatient’s card was used, which included sections of anamnesis, general 
clinical, instrumental and laboratory research.
The study of haemostatic parameters in venous blood was carried out immediately when the 
patient arrived at the department. The study of functional activity of platelets was performed on 
a Biola Aggregation Analyzer laser agrometer with a computerized analysis of light transmission 
curves and platelet aggregate features. In this case, the presence of spontaneous platelet aggregation 
and stimulated aggregation with inductors were studied: arachidonic acid (AA), adenosine diphos-
phate (ADP), collagen. Concentrations of inductors were selected according to the recommended 
standards, while the lowest effective concentrations that caused aggregation were used which in-
creased the sensitivity of this method in determining the functional activity of the platelets.
The  features  of  changes  in  platelet  activity were  confirmed  using  the Aggredyne  test,  a 
modern laser light scattering technique that detects the level of platelet aggregation induced by 
the arachidonic acid agonist and adenosine diphosphate when adding whole blood to the test car-
tridge-AA/ADP. The result is recorded by the platelet activity index (PAI).
DNA molecules of patients isolated from venous blood by a sorbent method were used for 
molecular genetic analysis. The polymorphism of the C807T of the ITGA2 gene was determined 
by polymerase chain reaction (PCR) using a two-particle system.
Based on the results of aggregation ability, antiplatelet therapy sensitivity, genotyping and 
according to the purpose of the study, all patients were divided into two groups: I group with dif-
ferent degrees of not sensitivity to antiplatelet drugs (35 patients), II group – sensitive to treatment 
(19 persons) Each group was analyzed on the polymorphism of the gene ITGA2 and features of 
the functional activity of the platelets, depending on the genotype. The control group consisted of 
15 practically healthy persons, matched by age and sex.
To solve the set tasks during the study were used a general clinical and instrumental exam-
ination of patients with a subsequent statistical treatment of the obtained results. Both parametric 
and nonparametric statistical methods were used: Kraskele Wallis and Mann-Whitney [19].
5. Results
The complex of conducted surveys allowed to find that the functional activity of platelets 
in the surveyed patients according to data such as spontaneous aggregation of platelets and all in-
vestigated inducers of platelet aggregation (ADP, AA, collagen) practically did not differ from the 
indicators of the control group, those who did not receive antiplatelet treatment (Table 1).
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Functional activity of platelets in the examined patients
Indicator Control (1) Patients after PCI (2) Р 1-2
Degree of spontaneous aggregation, % 0.88±0.31 1.87±1 >0.05
Degree of ADP induced aggregation, % 34.92±5.23 35.7±4.7 >0.05
Degree of AA induced aggregation, % 28.82±4.87 29.6±5.67 >0.05




therapy was performed using the Aggredyne test. The appropriate test cartridge was selected tak-
ing into account the mechanism of action of the drug: in patients receiving ASA, sensitivity was 
assessed using AA cartridges  (since  the effect of ASA  is  realized  through  the  influence on  the 
metabolism of arachidonic acid), in patients treated with clopidogrel - using ADP cartridges (given 
the effect of the drug on the ADP receptors of the platelet membrane). The difference in the degree 
of resistance to treatment in the application of the method indicated the value of the platelet index 
above 5 (Table 2).
Table 2




Patients receiving ASA (n=2) 50 % 50 %
Patients receiving clopidogrel (n=5) 80 % 20 %
Patients receiving dual therapy (n=47) 16.7 % 83.3 %
It was shown that among patients treated with ASA, a different degree of non-susceptibility 
to the drug was noted in 50 % of the subjects, with respect to thienopyridines -  this figure was 
lower and was 20 %. Among patients receiving dual antiplatelet therapy, 83.3 % of patients did not 
respond to at least one of the drugs used. Thus, it was concluded that a sufficiently large percent-
age of patients with coronary heart disease who received antiplatelet therapy after the PCI failed 
to respond to the treatment. In this regard, based on the Aggredyne test, two groups were formed, 
35 patients with varying degrees of non-susceptibility to treatment (non-responders) were included 
in group I, 19 patients in whom the test results were sufficient to respond to the drug, came in to 
the group II of respondents. Taking into account recent research on the role of the genetic factor in 
the development of resistance to antithrombotic treatment, it was decided to conduct a study on the 
effect of the polymorphism of the gene ITGA2 on the platelet response in patients with coronary 
artery disease after PCI. It was found that among patients who did not respond adequately to the 
treatment received, 78.9 % had a mutated T-allele, and a homozygous T-allele variant was recorded 
in 53.15 % of patients. Instead, among respondents this percentage was much lower and amounted 
to only 15.8 %. It should be noted that the overwhelming majority in the group of respondents was 
the group of the native genotype - С/С (Table 3).















Distribution  of  ITGA  2  genotypes  in  the  groups  of  patients  “non  responders”  and  “respondents”  on 
antiplatelet treatment




Concerning the aggregation induced AA – no similar effect was found.
Collagen aggregation data indicate that there is no significant effect of the mutation of the 
ITGA2 gene on the platelet sensitivity to collagen.




receptors of the platelet membrane) (Table 4).
Table 4
Features of changes in the functional activity of platelets in patients of the studied groups depending on the 
polymorphism of the gene ITGA 2
Indicator of  
platelet aggregation Group С/С С/Т Т/Т






























Note: * – p <0.05 in comparison with the group of “respondents”; ** – p=0.003 in comparison with the group of “respondents”
5. Discussion
Considering that the use of antiplatelet drugs is an integral part of the treatment of patients 
with coronary heart disease after PCI, the sensitivity question can be considered one of the main 
in determining the adequate prevention of thrombotic complications. The performed analysis of 
platelet  activity  in  this  category  of  patients  allowed  establishing  the  inadequate  efficacy  of  the 
antiplatelet agents that they were treated with (ASA, thienopyridines, and a combination of them). 
With the help of the Aggredyne-test, it was found that a different degree of antiplatelet resistance 
was found in 64.8 % of patients, which is consistent with the current literature, as noted in the study 
“Special antiplatelet  therapy can overcome resistance  to aspirin and clopidogrel” with a  total of 
504 patients among which 30.8 % was found with a low response to clopidogrel and 19.4 % with a 
low response rate to aspirin [10]. Also, in the study of the effect of the CYP2C19 gene on antithrom-








Among the possible causes of thrombocyte insensitivity to therapy are increasingly called 
genetic aspects [14, 20]. It deals with a large number of candidate genes, the polymorphism of 
which is associated with a change in the function and structure of the platelets. One of them is 
ITGA 2, whose genetic mutations cause increased propensity to thrombotic and complications 
associated with it [20].
The results of genotyping of patients and comparing the obtained data with the definition 
of sensitivity to antiplatelet therapy showed that the effect of polymorphism of the gene ITGA 2 on 
the functional platelet reactivity. In the vast majority of cases (78.9 %) among patients who did not 
respond to treatment, the mutant alleles of the gene were found, and 53.15 % of the surveyed cohort 
of “non-responders” appeared to be homozygotes on the T-allele (T/T genotype).
For comparison, in the group of patients, who were sensitive to antiplatelet therapy, only 
15.8 % had a T/T genotype. The obtained data suggest that the polymorphism of the gene ITGA 2, 
changing the adhesive ability of platelets by affecting their membrane receptors, creates the pre-
conditions for the development of resistance to antiplatelet drugs, the target of which are certain 




lower sensitivity to ASA, which, however, was not associated with the ITGA 2 polymorphism. This 
problem needs further investigation.
6. Conclusions
1. Functional activity of platelets in patients with coronary heart disease and post-PCI re-
ceiving antiplatelet (predominantly dual) therapy is almost the same as that of the control group, 
which indicates an inadequate treatment efficacy in this category of patients.
2. Among patients with coronary heart disease and after PCI,  in 64.8 % of cases,  there 
is a decrease in antiplatelet susceptibility that has a clear association with the polymorphism of 
genome IDGA2.
3. The presence of T-alleles in the genotype of patients with CHD is associated with a less 
adequate response of platelets in patients receiving dual antiplatelet therapy of ASA and thienopy-
ridines on ADP, which may have an effect on the sensitivity to thienopyridines.
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